AR011090A1 - COMPOSICIONES ANESTÉSICAS DE SEVOFLURANO, METODO PARA SU PREPARACIoN, MÉTODOS PARA INHIBIR SU DEGRADACIoN ANTE LA PRESENCIA DE UN ÁCIDO LEWIS Y UN PROCESO PARA PREPARAR UNA COMPOSICION ANESTÉSICA ESTABLE EN UN CONTENEDOR SELLADO - Google Patents

COMPOSICIONES ANESTÉSICAS DE SEVOFLURANO, METODO PARA SU PREPARACIoN, MÉTODOS PARA INHIBIR SU DEGRADACIoN ANTE LA PRESENCIA DE UN ÁCIDO LEWIS Y UN PROCESO PARA PREPARAR UNA COMPOSICION ANESTÉSICA ESTABLE EN UN CONTENEDOR SELLADO

Info

Publication number
AR011090A1
AR011090A1 ARP980100336A ARP980100336A AR011090A1 AR 011090 A1 AR011090 A1 AR 011090A1 AR P980100336 A ARP980100336 A AR P980100336A AR P980100336 A ARP980100336 A AR P980100336A AR 011090 A1 AR011090 A1 AR 011090A1
Authority
AR
Argentina
Prior art keywords
lewis acid
anesthetic
sevoflurane
degradation
inhibit
Prior art date
Application number
ARP980100336A
Other languages
English (en)
Original Assignee
Abbot Sarah C
Central Glass Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25148366&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR011090(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbot Sarah C, Central Glass Co Ltd filed Critical Abbot Sarah C
Publication of AR011090A1 publication Critical patent/AR011090A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Anesthesiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Catalysts (AREA)

Abstract

Una composicion anestésica que contiene un compuesto de fluoréter y un inhibidor de ácido Lewis fisiologicamente aceptable. Esta composicion exhibeuna estabilidad mejorada y no se degrada ante la presencia de un ácido Lewis. Un método para preparar la composicion anestésica y un método para inhibir ladegradacion de un compuesto fluoreter que tiene una porcion de alfa fluoreter ante la presencia de un ácido Lewis. En una forma de realizacion el compuestode fluoréter se seleccionadel grupo formado por sevoflurano, enflurano, isoflurano, metoxiflurano y desflurano. En una forma de realizacion el inhibidor de ácido Lewis se selecciona de un grupo formado por agua, hidroxitolueno butilado, metilparabeno, propilparabeno , propofol, otimol.
ARP980100336A 1997-01-27 1998-01-26 COMPOSICIONES ANESTÉSICAS DE SEVOFLURANO, METODO PARA SU PREPARACIoN, MÉTODOS PARA INHIBIR SU DEGRADACIoN ANTE LA PRESENCIA DE UN ÁCIDO LEWIS Y UN PROCESO PARA PREPARAR UNA COMPOSICION ANESTÉSICA ESTABLE EN UN CONTENEDOR SELLADO AR011090A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/789,679 US5990176A (en) 1997-01-27 1997-01-27 Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid

Publications (1)

Publication Number Publication Date
AR011090A1 true AR011090A1 (es) 2000-08-02

Family

ID=25148366

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP980100336A AR011090A1 (es) 1997-01-27 1998-01-26 COMPOSICIONES ANESTÉSICAS DE SEVOFLURANO, METODO PARA SU PREPARACIoN, MÉTODOS PARA INHIBIR SU DEGRADACIoN ANTE LA PRESENCIA DE UN ÁCIDO LEWIS Y UN PROCESO PARA PREPARAR UNA COMPOSICION ANESTÉSICA ESTABLE EN UN CONTENEDOR SELLADO
ARP060105042A AR057610A2 (es) 1997-01-27 2006-11-16 Composiciones anestesicas de sevoflurano, metodo para su preparacion, metodos para inhibir su degradacion ante la presencia de un acido lewis y un proceso para preparar una composicion anestesica estable en un contenedor sellado

Family Applications After (1)

Application Number Title Priority Date Filing Date
ARP060105042A AR057610A2 (es) 1997-01-27 2006-11-16 Composiciones anestesicas de sevoflurano, metodo para su preparacion, metodos para inhibir su degradacion ante la presencia de un acido lewis y un proceso para preparar una composicion anestesica estable en un contenedor sellado

Country Status (28)

Country Link
US (6) US5990176A (es)
EP (2) EP0967975B1 (es)
JP (5) JP3183520B2 (es)
KR (1) KR100368672B1 (es)
CN (3) CN1321958C (es)
AR (2) AR011090A1 (es)
AT (2) ATE320798T1 (es)
AU (1) AU726733B2 (es)
BG (2) BG109751A (es)
BR (1) BR9806996A (es)
CA (2) CA2626424A1 (es)
CO (1) CO4920220A1 (es)
CZ (1) CZ297092B6 (es)
DE (2) DE69800928T2 (es)
DK (2) DK0967975T3 (es)
ES (2) ES2256104T3 (es)
GR (1) GR3036190T3 (es)
HK (1) HK1074434A1 (es)
HU (1) HUP0002101A3 (es)
IL (1) IL130150A (es)
NO (1) NO993606L (es)
NZ (1) NZ335994A (es)
PL (1) PL334477A1 (es)
PT (2) PT967975E (es)
SK (1) SK284243B6 (es)
TR (1) TR199901579T2 (es)
WO (1) WO1998032430A1 (es)
ZA (1) ZA98418B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5990176A (en) * 1997-01-27 1999-11-23 Abbott Laboratories Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid
US20030200963A1 (en) * 1998-01-09 2003-10-30 Flament-Garcia Mary Jane Container for an inhalation anesthetic
US6074668A (en) * 1998-01-09 2000-06-13 Abbott Laboratories Container for an inhalation anesthetic
US6162443A (en) 1998-01-09 2000-12-19 Abbott Laboratories Container for an inhalation anesthetic
US7097849B2 (en) * 1998-08-19 2006-08-29 Jagotec Ag Injectable aqueous dispersions of propofol
EP1018827B1 (en) 1999-01-08 2004-05-06 Sony International (Europe) GmbH Synchronisation structure for OFDM system
TW523409B (en) 2000-09-15 2003-03-11 Baxter Int Container for inhalation anesthetic
WO2005023175A2 (en) * 2003-09-10 2005-03-17 Cristália Produtos Químicos Farmacêuticos Ltda. Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound
BR0303489A (pt) * 2003-09-10 2005-07-05 Cristalia Prod Quimicos Farm Composição farmacêutica estabilizada de composto flúor-éter e método para inibir a degradação de composto flúor-éter. uso de agente estabilizante para inibir a degradação de composto flúor éter
US20060258755A1 (en) * 2005-04-18 2006-11-16 Terrell Ross C Preparation of sevoflurane with negligible water content
WO2009049460A1 (fr) * 2007-10-15 2009-04-23 Jiangsu Hengrui Medicine Co., Ltd. Nouveau matériau conditionné de sévoflurane
EP3581169A1 (en) * 2008-01-22 2019-12-18 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
US20090275785A1 (en) * 2008-05-01 2009-11-05 Barry Jones Distillation Method For The Purification Of Sevoflurane And The Maintenance Of Certain Equipment That May Be Used In The Distillation Process
US8563115B2 (en) 2008-08-12 2013-10-22 Xerox Corporation Protective coatings for solid inkjet applications
US8092822B2 (en) * 2008-09-29 2012-01-10 Abbott Cardiovascular Systems Inc. Coatings including dexamethasone derivatives and analogs and olimus drugs
US8283643B2 (en) * 2008-11-24 2012-10-09 Cymer, Inc. Systems and methods for drive laser beam delivery in an EUV light source
US8191992B2 (en) * 2008-12-15 2012-06-05 Xerox Corporation Protective coatings for solid inkjet applications
US9278048B2 (en) * 2009-05-06 2016-03-08 Baxter International, Inc. Pharmaceutical product and method of use
US9102604B1 (en) 2010-02-15 2015-08-11 Baxter International Inc. Methods for cleaning distilling columns
CN105106182B (zh) * 2015-09-21 2017-12-29 山东新时代药业有限公司 七氟烷吸入剂
CN105193774B (zh) * 2015-09-21 2018-01-16 山东新时代药业有限公司 一种七氟烷吸入剂
BE1024432B1 (fr) * 2016-11-02 2018-02-19 Central Glass Company, Limited Procédé pour le lavage de récipient de stockage de sévoflurane et procédé pour le stockage de sévoflurane

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2992276A (en) * 1959-05-20 1961-07-11 Du Pont Process for preparing polyfluoro alkyl compounds
US3527813A (en) * 1966-10-03 1970-09-08 Air Reduction 1,1,2 - trifluoro - 2 - chloroethyl difluoromethyl ether and its method of preparation
US3689571A (en) * 1970-07-31 1972-09-05 Baxter Laboratories Inc Fluorinated ether
GB1499818A (en) * 1974-12-06 1978-02-01 Ici Ltd Anaesthetic composition
US4469898A (en) * 1979-12-26 1984-09-04 Baxter Travenol Laboratories, Inc. Method of synthesizing fluoromethylhexafluoroisopropyl ether
US4250334A (en) * 1979-12-26 1981-02-10 Baxter Travenol Laboratories, Inc. Method of synthesizing fluoromethylhexafluoroisopropyl ether
JP2786108B2 (ja) * 1994-03-31 1998-08-13 セントラル硝子株式会社 フルオロメチル−１，１，１，３，３，３−ヘキサフルオロイソプロピルエーテルの精製方法
IT1270239B (it) * 1994-06-17 1997-04-29 Zambon Spa Composizione farmaceutica solida contenente acido (s)-2-(4- isobutilfenil) propionico come principio attivo
US5990176A (en) 1997-01-27 1999-11-23 Abbott Laboratories Fluoroether compositions and methods for inhibiting their degradation in the presence of a Lewis acid

Also Published As

Publication number Publication date
DK1114641T3 (da) 2006-05-15
NO993606L (no) 1999-09-24
US20060148906A1 (en) 2006-07-06
US20020016373A1 (en) 2002-02-07
BR9806996A (pt) 2000-03-14
CN1560003A (zh) 2005-01-05
EP0967975B1 (en) 2001-06-13
US20030130359A1 (en) 2003-07-10
US6677492B2 (en) 2004-01-13
CZ297092B6 (cs) 2006-09-13
KR100368672B1 (ko) 2003-01-24
NO993606D0 (no) 1999-07-23
PT967975E (pt) 2001-11-30
CA2278133A1 (en) 1998-07-30
HK1074434A1 (en) 2005-11-11
NZ335994A (en) 2000-08-25
CN1321958C (zh) 2007-06-20
BG65414B1 (bg) 2008-07-31
PL334477A1 (en) 2000-02-28
CN1899271A (zh) 2007-01-24
SK86199A3 (en) 2000-06-12
AU5930098A (en) 1998-08-18
JP3183520B2 (ja) 2001-07-09
ZA98418B (en) 1999-04-20
US6288127B1 (en) 2001-09-11
EP1114641B1 (en) 2006-03-22
CN1152674C (zh) 2004-06-09
IL130150A (en) 2004-09-27
JP2005279283A (ja) 2005-10-13
WO1998032430A1 (en) 1998-07-30
US20040048932A1 (en) 2004-03-11
CZ256199A3 (cs) 1999-11-17
DE69833884D1 (de) 2006-05-11
ATE320798T1 (de) 2006-04-15
GR3036190T3 (en) 2001-10-31
AR057610A2 (es) 2007-12-05
JP2006143742A (ja) 2006-06-08
DK0967975T3 (da) 2001-09-17
CN1244797A (zh) 2000-02-16
AU726733B2 (en) 2000-11-16
HUP0002101A2 (hu) 2001-05-28
CA2278133C (en) 2001-06-26
TR199901579T2 (xx) 1999-12-21
BG109751A (bg) 2008-06-30
DE69800928D1 (de) 2001-07-19
DE69800928T2 (de) 2001-11-22
JP2006137769A (ja) 2006-06-01
IL130150A0 (en) 2001-03-19
PT1114641E (pt) 2006-05-31
DE69833884T2 (de) 2006-08-24
EP0967975A1 (en) 2000-01-05
JP2001187729A (ja) 2001-07-10
BG103656A (en) 2000-04-28
EP1114641A3 (en) 2003-05-28
JP3664648B2 (ja) 2005-06-29
EP1114641A2 (en) 2001-07-11
US6444859B2 (en) 2002-09-03
US5990176A (en) 1999-11-23
ES2256104T3 (es) 2006-07-16
CA2626424A1 (en) 1998-07-30
ATE201987T1 (de) 2001-06-15
KR20000070482A (ko) 2000-11-25
HUP0002101A3 (en) 2002-03-28
CO4920220A1 (es) 2000-05-29
SK284243B6 (sk) 2004-12-01
JP2000510159A (ja) 2000-08-08
ES2170474T3 (es) 2002-08-01

Similar Documents

Publication Publication Date Title
AR011090A1 (es) COMPOSICIONES ANESTÉSICAS DE SEVOFLURANO, METODO PARA SU PREPARACIoN, MÉTODOS PARA INHIBIR SU DEGRADACIoN ANTE LA PRESENCIA DE UN ÁCIDO LEWIS Y UN PROCESO PARA PREPARAR UNA COMPOSICION ANESTÉSICA ESTABLE EN UN CONTENEDOR SELLADO
AR027060A1 (es) Bases de mannich de 1-naftol y 2-naftol sustituidos, procedimiento para su preparacion, medicamentos que contienen estos compuestos, asi como el uso deestos compuestos para la fabricacion de medicamentos
CY1107438T1 (el) Παραγωγα καρβοξυλικου οξεος, τα οποια παρεμποδιζουν την συνδεσιν ιντεγκρινων εις τους υποδοχεις των
MX9205208A (es) Compuestos derivados del acido 5-amino-4-hidroxihexanoico, procedimiento para su preparacion y compociciones farmaceuticas que los contienen
CL2009001682A1 (es) Composición farmacéutica espontáneamente dispersable para administración oral que comprende n-benzoil-estaurosporina; método para incrementar los niveles de biodisponibilidad. (divisional de la solocitud 333-00).
ES2155872T3 (es) Triestannoxanos.
ES2192256T3 (es) Soluciones farmaceuticas inyectables que contienen paracetamol y combinaciones de paracetamol con otras sustancias activas.
AR009911A1 (es) Derivados de acido benzazepinona-n-acetico, sustituidos con acidos fosfonicos, asi como procedimientos para su preparacion y medicamentos que contienen estos compuestos
CO4960655A1 (es) Nueva composicion y su uso
MX9201324A (es) Nuevos compuestos para inhibir la secrecion acida gastrica en mamiferos, procedimiento para su preparacion y composicion farmaceutica que los contiene.
GB9928820D0 (en) Stable high glycerol liquids comprising sulfosuccinic acid monoesters
AR012546A1 (es) Utilizacion de al menos un compuesto seleccionado entre el grupo que comprende los sogaoles y los gingeroles para la preparacion de una composiciondesodorante, sogaol, extracto bruto y extracto purificado que contiene el sogaol y la composicion desodorante obtenida.
EP1115478A4 (en) EMOLLIENT ESTERS BASED ON CAPRYLIC ALCOHOL AND ISOSTEARIC ACID
ES2011041B3 (es) Procedimiento para la obtencion de aldehidos alifaticos y su empleo como perfumes.
MX9207427A (es) Nuevos compuestos de ester de butilhidroxitolueno-omega-piridilo y composicion farmaceutica que los contiene.
WO2005023175B1 (en) Stable pharmaceutical composition of fluoroether compound for anesthetic use, method for stabilizing a fluoroether compound, use of stabilizer agent for precluding the degradation of a fluoroether compound
UY26507A1 (es) Bases de mannich de 1-naftol y 2-naftol sustituidos, procedimiento para su preparación, medicamentos que contienen estos compuestos, así como el uso de estos compuestos para la preparación de medicamentos
MX9400038A (es) Composiciones y metodos para proveer un efecto analgesico mejorado.
AR240401A1 (es) Procedimiento para obtener aceite de manzanilla con un contenido de espiroeteres naturales superior al 5%, del tipo que comprende destilar con agua o vapor de agua flores de manzanilla en caso dado en presencia de agentes reductores, porque la destilacio
PT1143962E (pt) Solucao parenterica de propofol (2,6-di-isopropilfenol) e 2,5-di-o-metil-1,4;3,6-di-anidro-d-glucitol, como dissolvente
IT1204778B (it) Formulazioni farmaceutiche iniettabili di principi attivi ad attivita' anestetica generale
EA200100047A1 (ru) Противостаритель для гликолей или гликольэфиров
CA2352597A1 (en) Fluoroether compositions and methods for inhibiting their degradation in the presence of a lewis acid
JPS5618958A (en) Preparation of n- d-alpha-methyl-beta-mercaptopropionyl -l- proline derivative
NO940229D0 (no) Esterblanding

Legal Events

Date Code Title Description
FG Grant, registration